Immunic (NASDAQ:IMUX) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

A number of other analysts have also commented on IMUX. HC Wainwright cut their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Roth Mkm assumed coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.40.

Immunic Price Performance

IMUX stock opened at $0.59 on Tuesday. The stock has a market capitalization of $70.85 million, a P/E ratio of -0.71 and a beta of 1.58. Immunic has a fifty-two week low of $0.51 and a fifty-two week high of $1.39. The business has a 50-day moving average of $0.63 and a 200-day moving average of $0.77.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. Equities analysts expect that Immunic will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMUX. Qube Research & Technologies Ltd bought a new stake in Immunic in the 3rd quarter valued at $29,000. Two Sigma Investments LP acquired a new position in shares of Immunic in the third quarter valued at $52,000. HB Wealth Management LLC bought a new position in shares of Immunic in the third quarter valued at about $81,000. Virtu Financial LLC bought a new position in shares of Immunic in the third quarter valued at about $99,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Immunic during the 3rd quarter worth about $170,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.